NCT06607185 2026-03-13A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid TumorsEli Lilly and CompanyPhase 1 Active not recruiting750 enrolled
NCT00499291 2023-05-25Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Advanced or Refractory Solid TumorsEastern Cooperative Oncology GroupPhase NA Withdrawn
NCT00028535 2013-06-04Interleukin-12, Paclitaxel, and Trastuzumab in Treating Patients With Solid TumorsNational Cancer Institute (NCI)Phase 1 Completed18 enrolled